1. Spinal cathepsin S and fractalkine contribute to chronic pain in the collagen-induced arthritis model.
- Author
-
Clark AK, Grist J, Al-Kashi A, Perretti M, and Malcangio M
- Subjects
- Animals, Antibodies, Neutralizing pharmacology, Cathepsins antagonists & inhibitors, Chemokine CX3CL1 antagonists & inhibitors, Dipeptides pharmacology, Female, Microglia drug effects, Neurons drug effects, Neurons metabolism, Rats, Rats, Inbred Lew, Spinal Cord drug effects, Sulfones pharmacology, Arthritis, Experimental metabolism, Cathepsins metabolism, Chemokine CX3CL1 metabolism, Chronic Pain metabolism, Hyperalgesia metabolism, Microglia metabolism, Spinal Cord metabolism
- Abstract
Objective: The induction of rheumatoid arthritis (RA) by active and passive immunization of mice results in the development of pain at the same time as the swelling and inflammation, with both peripheral and central sensitization contributing to joint pain. The purpose of this study was to examine the development of pain in the rat model of collagen-induced arthritis (CIA) and to evaluate the contribution of neuroimmune interactions to established arthritis pain., Methods: Mechanical hypersensitivity was assessed in female Lewis rats before and up to 18 days after induction of CIA by immunization with type II collagen. The effect of selective inhibitors of microglia were then evaluated by prolonged intrathecal delivery of a cathepsin S (CatS) inhibitor and a fractalkine (FKN) neutralizing antibody, from day 11 to day 18 following immunization., Results: Rats with CIA developed significant mechanical hypersensitivity, which started on day 9, before the onset of clinical signs of arthritis. Mechanical hypersensitivity peaked with the severity of the disease, when significant microglial and astrocytic responses, alongside T cell infiltration, were observed in the spinal cord. Intrathecal delivery of microglial inhibitors, a CatS inhibitor, or an FKN neutralizing antibody attenuated mechanical hypersensitivity and spinal microglial response in rats with CIA., Conclusion: The inhibition of microglial targets by centrally penetrant CatS inhibitors and CX(3) CR1 receptor antagonists represents a potential therapeutic avenue for the treatment of pain in RA., (Copyright © 2012 by the American College of Rheumatology.)
- Published
- 2012
- Full Text
- View/download PDF